Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Middle-aged folks and seniors whose weed use lands them in the hospital are at higher risk for developing dementia within a ...

We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

Danuglipron: According to the company's latest statement, one patient experienced a potential liver injury that may have been ...